Abstract
Osteolysis resulting from osteoclast overactivation is one of the severe complications of breast cancer metastasis to the bone. Previous studies reported that the anti-cancer agent DZNep induces cancer cell apoptosis but paradoxically activates Akt signaling. We previously found that DZNep enhances osteoclast differentiation via this Akt activation. Therefore, we explored the use of the Akt inhibitor AZD3463 alongside DZNep to ameliorate bone erosion while maintaining anti-cancer efficacy. In vitro and in vivo evaluations demonstrated that this combination inhibits breast cancer cell proliferation, migration, and invasion while simultaneously protecting against tumor-induced bone loss. Our findings suggest that DZNep combined with AZD3463 prevents skeletal complications and inhibits breast cancer progression by suppressing the Akt signaling axis.
Introduction: The Vicious Cycle of Bone Metastasis
Breast cancer has a high affinity for bone metastasis, which often triggers a "vicious cycle." Cancer cells in the bone microenvironment secrete factors that overactivate osteoclasts—cells responsible for breaking down bone. This bone destruction releases growth factors that further fuel tumor progression. Breaking this cycle requires a dual-action therapeutic approach that targets both the tumor cells and the pathological bone remodeling process.
The DZNep-Akt Paradox
DZNep is a promising anti-cancer agent that targets the EZH2 protein. However, its clinical utility in bone metastasis is complicated by an "off-target" effect: it activates the Akt signaling pathway. In osteoclast precursors, this activation accelerates differentiation and bone erosion, potentially worsening the metastatic environment. By introducing AZD3463, a potent Akt inhibitor, we aimed to neutralize this harmful impact on bone health while enhancing DZNep's anti-tumor effects.
Methods and Viability Testing
The researchers employed Bone Marrow-derived Macrophages (BMMs) to study osteoclasts and human/mouse breast cancer lines (MDA-MB-231 and 4T1) for tumor assays. A critical first step was establishing the non-toxic dosage range for the inhibitors using CCK-8 cell viability assays to ensure that observed effects on differentiation or migration were not due to simple cell death.
Results: Synergistic Suppression of Tumor and Osteoclasts
Reversing Osteoclast Overactivation
In vitro, DZNep alone significantly increased the number of TRAP-positive osteoclasts and the area of bone resorption pits. The addition of AZD3463 (250 nM) effectively reversed these effects, confirming that the pro-osteoclastogenic impact of DZNep is mediated through the Akt pathway.
Enhanced Anti-Tumor Efficacy
The combination treatment significantly reduced breast cancer cell colony formation and invasion compared to monotherapy. In wound healing assays, the combination group showed the slowest rate of migration, indicating a synergistic inhibition of the metastatic phenotype.
In Vivo Bone Preservation
In a mouse model of bone metastasis, Micro-CT analysis of the tibiae showed that the combination therapy group maintained significantly higher Bone Volume/Total Volume (BV/TV) and trabecular numbers compared to the DZNep-only group. Histological analysis confirmed the smallest tumor volumes in the combination group, with no observed systemic toxicity in the liver or kidneys.
Conclusion
This study identifies a synergistic drug combination—DZNep and AZD3463—that simultaneously attacks breast cancer cells and prevents the bone destruction typically associated with metastasis. By using the Akt inhibitor AZD3463 to block the paradoxical side effects of DZNep, we successfully inhibited tumor progression and preserved bone integrity in animal models, offering a potential new strategy for managing skeletal complications in breast cancer patients.
Summary updated